Antibody-drug conjugates for cancer therapy

Cancer Journal

Volumn 14, Issue 3, 2008, Pages 154-169

  Carter, Paul J ^a   Senter, Peter D ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

Antibody; Immunoconjugate; Targeted therapy

Indexed keywords

ANSAMITOCIN; ANTIBODY CONJUGATE; AVE 9633; BIIB015; CALICHEAMICIN; CETUXIMAB; CR 011; DOXORUBICIN; FC RECEPTOR; GEMTUZUMAB OZOGAMICIN; HUC242 DM4; HUN901 DM1; IBRITUMOMAB TIUXETAN; IMGN 242; IMGN 901; IMMUNOGLOBULIN G; INOTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY J591; MONOMETHYL AURISTATIN E; PANITUMUMAB; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RITUXIMAB; SAR 3419; SGN 35; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; AMINOGLYCOSIDE; GEMTUZUMAB; IMMUNOLOGIC FACTOR; IMMUNOTOXIN; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIBODY RESPONSE; ANTIBODY SCREENING; ANTIGEN BINDING; ANTIGEN EXPRESSION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B CELL LYMPHOMA; BINDING AFFINITY; BONE MARROW SUPPRESSION; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; CORNEA DISEASE; CORNEAL DEPOSIT; DEHYDRATION; DIARRHEA; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG MEGADOSE; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DYSPNEA; GASTROINTESTINAL TOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOTENSION; KERATITIS; LEUKOPENIA; LEWIS CARCINOMA; LIVER TOXICITY; LUNG SMALL CELL CANCER; MELANOMA; METASTASIS; MONOTHERAPY; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; SEPSIS; SIDE EFFECT; SMALL CELL CARCINOMA; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION; VISUAL ACUITY; BIOSYNTHESIS; METABOLISM; NEOPLASM;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; IMMUNOTOXINS; NEOPLASMS; RECEPTORS, FC;

EID: 49449119098     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318172d704     Document Type: Review

References (171)

1. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov. 2007;6:349-356.
2. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343-357.
3. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006;5:147-159.
4. Weiner LM. Building better magic bullets - improving unconjugated monoclonal antibody therapy for cancer. Nat Rev Cancer. 2007;7:701- 706.
5. Desjarlais JR, Lazar GA, Zhukovsky EA, et al. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today. 2007;12:898-910.
6. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol. 2005;5:543-549.
7. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-1496.
8. Moolten FL, Cooperband SR. Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science. 1970;169:68-70.
9. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.
10. Carter P, Smith L, Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer. 2004;11:659-687.
11. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23:1137-1146.
12. Brumlik MJ, Daniel BJ, Waehler R, et al. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy. Expert Opin Drug Deliv. 2008;5:87-103.
13. Blättler WA. In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer. Exp Opin Biol Ther. 2006;6:281-291.
14. Ricart AD, Tolcher AW. Technology insight: cytotoxic drug immuno-conjugates for cancer therapy. Nat Clin Pract Oncol. 2007;4:245-255.
15. Cheson BD. Radioimmunotherapy of non-Hodgkin's lymphomas. Curr Drug Targets. 2006;7:1293-1300.
16. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
17. Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat Rev Drug Discov. 2003;2:962-972.
18. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002;1: 304-313.
19. Schliemann C, Neri D. Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta. 2007;1776:175-192.
20. Simonson AB, Schnitzer JE. Vascular proteomic mapping in vivo. J Thromb Haemost. 2007;5[suppl 1]:183 187.
21. Henry MD, Wen S, Silva MD, et al. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 2004;64:7995-8001.
22. Ma D, Hopf CE, Malewicz AD, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res. 2006;12:2591-2596.
23. Tanimoto M, Scheinberg DA, Cordon-Cardo C, et al. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia. 1989;3:339-348.
24. Liu C, Tadayoni BM, Bourret LA, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci USA. 1996;93:8618-8623.
25. Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66:3214-3221.
26. Okeley NM, Alley SC, Cerveny CG, et al. Specific tumor targeting and potent bystander killing with SGN-35, an anti-CD30 antibody drug conjugate [abstract]. Blood. 2006;108:231.
27. Clavio M, Vignolo L, Albarello A, et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol. 2007;138:186-195.
28. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111:3941-3967.
29. Tijink BM, Buter J, de Bree R, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006;12:6064-6072.
30. Tolcher AW, Sugarman S, Gelmon KA, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 1999;17:478-484.
31. Drewinko B, Patchen M, Yang LY, et al. Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res. 1981;41:2328-2333.
32. Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett. 2007;255:232-240.
33. Fosella F, McCann J, Tolcher A, et al. Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma [abstract]. J Clin Oncol. 2005;23:7159.
34. Chan SY, Gordon AN, Coleman RE, et al. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother. 2003;52:243-248.
35. Beeram M, Krop I, Modi S, et al. A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC) [abstract]. J Clin Oncol. 2007;25 Abstract 1042.
36. Krop IE, Beeram M, Modi S, et al. A phase I study of trastuzumabDM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer. 30th Annual San Antonio Breast Cancer Symposium. 2007 Abstract 310.
37. Law CL, Cerveny CG, Gordon KA, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res. 2004;10:7842-7851.
38. Dijoseph JF, Dougher MM, Armellino DC, et al. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab. Cancer Immunol Immunother. 2007;56:1107-1117.
39. Ingle GS, Chan P, Elliott JM, et al. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br J Haematol. 2008;140:46-58.
40. Klussman K, Mixan BJ, Cerveny CG, et al. Secondary mAb-vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway. Bioconjug Chem. 2004;15:765-773.
41. Lonberg N. Human monoclonal antibodies from transgenic mice. Handb Exp Pharmacol. 2008;69-97.
42. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol. 2005;23:1105-1116.
43. Mondon P, Dubreuil O, Bouayadi K, et al. Human antibody libraries: a race to engineer and explore a larger diversity. Front Biosci. 2008; 13:1117-1129.
44. Almagro JC, Fransson J. Humanization of antibodies. Front Biosci. 2008;13:1619-1633.
45. Becerril B, Poul MA, Marks JD. Toward selection of internalizing antibodies from phage libraries. Biochem Biophys Res Commun. 1999; 255:386-393.
46. Declerck PJ, Carmeliet P, Verstreken M, et al. Generation of monoclonal antibodies against autologous proteins in gene-inactivated mice. J Biol Chem. 1995;270:8397-8400.
47. Goding JW. Monoclonal Antibodies: Principles and Practice. 3rd ed. San Diego: Academic Press 1996:400-423.
48. Smith DB, Johnson KS. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. 1988;67:31-40.
49. Dalum I, Jensen MR, Hindersson P, et al. Breaking of B cell tolerance toward a highly conserved self protein. J Immunol. 1996;157:4796-4804.
50. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther. 2007;7:1401-1413.
51. Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol. 2007;25:1369-1372.
52. Presta LG. Engineering antibodies for therapy. Curr Pharm Biotechnol. 2002;3:237-256.
53. Yoo EM, Wims LA, Chan LA, et al. Human IgG2 can form covalent dimers. J Immunol. 2003;170:3134-3138.
54. Jakobovits A, Amado RG, Yang X, et al. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol. 2007;25:1134-1143.
55. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49:673-680.
56. Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology. 2002;105:9-19.
57. van der Neut Kolfschoten M, Schuurman J, Losen M, et al. Antiinflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317:1554-1557.
58. Zuckier LS, Georgescu L, Chang CJ, et al. The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer. 1994;73:794-799.
59. Sondermann P, Huber R, Oosthuizen V, et al. The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature. 2000;406:267-273.
60. Ghetie V, Ward ES. Transcytosis and catabolism of antibody. Immunol. Res. 2002;25:97-113.
61. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715-725.
62. Ober RJ, Martinez C, Lai X, et al. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci USA. 2004;101:11076-11081.
63. Ober RJ, Martinez C, Vaccaro C, et al. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol. 2004;172:2021-2029.
64. West AP Jr, Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry. 2000;39:9698-9708.
65. Hinton PR, Johlfs MG, Xiong JM, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem. 2004;279:6213-6216.
66. Hinton PR, Xiong JM, Johlfs MG, et al. An engineered human IgG1 antibody with longer serum half-life. J Immunol. 2006;176:346-356.
67. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281:23514-23524.
68. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem. 2001;276:6591-6604.
69. Martin WL, West AP Jr, Gan L, et al. Crystal structure at 2. 8 Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell. 2001;7:867-877.
70. Gillies SD, Wesolowski JS. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities. Hum Antibodies Hybridomas. 1990;1:47-54.
71. Dall'Acqua WF, Cook KE, Damschroder MM, et al. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol. 2006;177:1129-1138.
72. Wang L, Amphlett G, Blättler WA, et al. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci. 2005;14:2436-2446.
73. McDonagh CF, Turcott E, Westendorf L, et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel. 2006;19:299-307.
74. Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol. 2000;18:2282-2292.
75. Tolcher AW, Ochoa L, Hammond LA, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol. 2003;21:211-222.
76. Sanderson RJ, Hering MA, James SF, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 2005;11:843-852.
77. Pietersz GA, Rowland A, Smyth MJ, et al. Chemoimmunoconjugates for the treatment of cancer. Adv Immunol. 1994;56:301-387.
78. Dubowchik GM, Walker MA. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther. 1999; 83:67-123.
79. Trail PA, Willner D, Lasch SJ, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 1993; 261:212-215.
80. Chari RV, Jackel KA, Bourret LA, et al. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res. 1995;55:4079-4084.
81. Chari RV, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. 1992; 52:127-131.
82. Hinman LM, Hamann PR, Wallace R, et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993;53: 3336-3342.
83. Okamoto K, Harada K, Ikeyama S, et al. Therapeutic effect of ansami-tocin targeted to tumor by a bispecific monoclonal antibody. Jap J Cancer Res. 1992;83:761-768.
84. Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol. 2003;3:386-390.
85. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41:98-107.
86. Jeffrey SC, Nguyen MT, Moser RF, et al. Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker. Bioorg Med Chem Lett. 2007;17:2278-2280.
87. Sedalacek H-H, Seemann G, Hoffmann D, et al. Antibodies as Carriers of Cytotoxicity, Vol. 43. Munich, Germany: Karger, 1992.
88. I. J Am Chem Soc. 1987;109:3464-3466.
89. Boghaert ER, Khandke KM, Sridharan L, et al. Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples. Cancer Chemother Pharmacol. 2008;61:1027-1035.
90. Hamann PR, Hinman LM, Beyer CF, et al. An anti-MUC1 antibody- calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Bioconjug Chem. 2005;16:346-353.
91. Hamann PR, Hinman LM, Beyer CF, et al. An anti-CD33 antibodycalicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem. 2002;13:40-46.
92. DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103:1807-1814.
93. DiJoseph JF, Goad ME, Dougher MM, et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res. 2004;10:8620-8629.
94. DiJoseph JF, Popplewell A, Tickle S, et al. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol Immunother. 2005;54:11-24.
95. Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13:47-58.
96. Y-positive human carcinoma cells and xenografts. Clin Cancer Res. 2004;10:4538-4549.
97. Boghaert ER, Sridharan L, Khandke KM, et al. The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin. Int J Oncol. 2008;32:221-234.
98. Lode HN, Reisfeld RA, Handgretinger R, et al. Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. Cancer Res. 1998;58:2925-2928.
99. Schmidt CS, Wrasidlo W, Kaufmann O, et al. Monoclonal antibody 138H11 against gamma-glutamyltransferase provides a possible tool for targeting calicheamicin theta to renal cell carcinomas. Adv Exp Med Biol. 1998;451:431-436.
100. Hamann PR, Hinman LM, Beyer CF, et al. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. Bioconjug Chem. 2005;16:354-360.
101. Boghaert ER, Khandke K, Sridharan L, et al. Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. Int J Oncol. 2006;28:675-684.
102. Jedema I, Barge RM, van der Velden VH, et al. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia. 2004;18:316-325.
103. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778-784.
104. Yu TW, Bai L, Clade D, et al. The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum. Proc Natl Acad Sci USA. 2002;99:7968-7973.
105. Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006; 17:114-124.
106. Bai R, Pettit GR, Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol. 1990;39:1941-1949.
107. Mills BJ, Lang CA. Differential distribution of free and bound glutathione and cyst(e)ine in human blood. Biochem Pharmacol. 1996;52: 401-406.
108. Helft PR, Schilsky RL, Hoke FJ, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004;10: 4363-4368.
109. Widdison WC, Wilhelm SD, Cavanagh EE, et al. Semisynthetic may-tansine analogues for the targeted treatment of cancer. J Med Chem. 2006;49:4392-4408.
110. v integrin-targeted immunoconjugates regress established human tumors in xenograft models. Clin Cancer Res. 2007;13:3689-3695.
111. Aboukameel A, Goustin A-S, Mohammad R, et al. Superior anti-tumor activity of the CD19-directed immunotoxin, SAR3419 to rituximab in non-Hodgkin's xenograft animal models: preclinical evaluation [abstract]. Blood. 2007;110:2339.
112. Legrand O, Vidriales MB, Thomas X, et al. An open label, dose escalation study of AVE9633 administered as a single agent by intravenous (IV) infusion weekly for 2 weeks in 4-week cycle to patients with relapsed or refractory CD33-positive acute myeloid leukemia (AML) [abstract]. Blood. 2007;110:1850.
113. Tassone P, Gozzini A, Goldmacher V, et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl- N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004;64:4629-4636.
114. Polson AG, Yu SF, Elkins K, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007; 110:616-623.
115. Tassone P, Goldmacher VS, Neri P, et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004;104:3688-3696.
116. Ranson M, Sliwkowski MX. Perspectives on anti-HER monoclonal antibodies. Oncology. 2002;63[suppl 1]:17-24.
117. Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 2002;62:2546-2553.
118. Dubowchik GM, Firestone RA. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg Med Chem Lett. 1998;8:3341-3346.
119. Dubowchik GM, Mosure K, Knipe JO, et al. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett. 1998;8:3347-3352.
120. Walker MA, Dubowchik GM, Hofstead SJ, et al. Synthesis of an immunoconjugate of camptothecin. Bioorg Med Chem Lett. 2002;12: 217-219.
121. Walker MA, King HD, Dalterio RA, et al. Monoclonal antibody mediated intracellular targeting of tallysomycin S(10b). Bioorg Med Chem Lett. 2004;14:4323-4327.
122. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458-1465.
123. Ryan MC, Hering M, Peckham D, et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther 2007;6:3009-3018.
124. Benjamin D, Morris-Tilden C, Stone I, et al. Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies. AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics. 2007: Abstract B60.
125. Law CL, Gordon KA, Toki BE, et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res. 2006;66:2328-2337.
126. Bhaskar V, Law DA, Ibsen E, et al. E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res. 2003;63: 6387-6394.
127. Mao W, Luis E, Ross S, et al. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res. 2004;64:781-788.
128. Tse KF, Jeffers M, Pollack VA, et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res. 2006;12:1373-1382.
129. Chen Y, Clark S, Wong T, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007;67:4924-4932.
130. Afar DE, Bhaskar V, Ibsen E, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther. 2004;3:921-932.
131. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66:4426-4433.
132. Alley SC, Benjamin DR, Jeffrey SC, et al. The contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19:759-765.
133. King HD, Dubowchik GM, Mastalerz H, et al. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. J Med Chem. 2002;45:4336-4343.
134. Hollander I, Kunz A, Hamann PR. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjug Chem. 2008;19:358-361.
135. Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063-7070.
136. Hamblett KJ, Barton J, Cerveny CG, et al. SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30+ malignancies [abstract]. Blood. 2005;106:610.
137. Younes A, Forero-Torres A, Bartlett N, et al. A novel antibody-drug conjugate, SGN-35 (anti-CD30-auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma, preliminary results of a phase I tolerability study. 7th International Symposium on Hodgkin Lymphoma. 2007.
138. Sun MM, Beam KS, Cerveny CG, et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem. 2005;16:1282-1290.
139. Lyons A, King DJ, Owens RJ, et al. Site-specific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Eng. 1990;3:703-708.
140. Stimmel JB, Merrill BM, Kuyper LF, et al. Site-specific conjugation on serine - cysteine variant monoclonal antibodies. J Biol Chem. 2000; 275:30445-30450.
141. Caron PC, Laird W, Co MS, et al. Engineered humanized dimeric forms of IgG are more effective antibodies. J Exp Med. 1992;176:1191-1195.
142. Shopes B. A genetically engineered human IgG mutant with enhanced cytolytic activity. J Immunol. 1992;148:2918-2922.
143. Shopes B. A genetically engineered human IgG with limited flexibility fully initiates cytolysis via complement. Mol Immunol. 1993;30:603-609.
144. Junutula JR, Bhakta S, Raab H, et al. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods. 2008; 332:41-52.
145. Gleissner B, Schlenk R, Bornhauser M, et al. Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia-ongoing trials. Onkologie. 2007;30:657-662.
146. Pagano L, Fianchi L, Caira M, et al. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene. 2007;26:3679-3690.
147. Tsimberidou AM, Giles FJ, Estey E, et al. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 2006;132:398-409.
148. Legrand O, Perrot JY, Baudard M, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood. 2000;96:870-877.
149. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104:1442-1452.
150. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92:406-413.
151. Rajvanshi P, Shulman HM, Sievers EL, et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99:2310-2314.
152. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254.
153. Burnett AK, Kell WJ, Goldstone AH, et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial. [abstract] Blood. 2006;108:13.
154. Pollack VA, Alvarez E, Tse KF, et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol. 2007;60:423-435.
155. Sznol M, Sanders D, Kluger H, et al. Phase I pharmacokinetic study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma. AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics. 2007:Abstract B47.
156. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89:4285-4289.
157. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244:707-712.
158. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
159. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36.
160. DiJoseph JF, Dougher MM, Kalyandrug LB, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against nonHodgkin's B-cell lymphoma. Clin Cancer Res. 2006;12:242-249.
161. Baeckstrom D, Hansson GC, Nilsson O, et al. Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins. J Biol Chem. 1991;266:21537-21547.
162. Haglund C, Lindgren J, Roberts PJ, et al. Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Br J Cancer. 1989;60:845-851.
163. Mita MM, Ricart AD, Mita AC, et al. A phase I study of a CanAgtargeted immunoconjugate, huC242-DM4, in patients with Can Agexpressing solid tumors [abstract]. J Clin Oncol. 2007;25:3062.
164. Jensen M, Berthold F. Targeting the neural cell adhesion molecule in cancer. Cancer Lett. 2007;258:9-21.
165. McCann J, Fossella FV, Villalona-Calero MA, et al. Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma [abstract]. J Clin Oncol. 2007;25:18084.
166. Chanan-Khan AA, Jagannath S, Munshi NC, et al. Phase I study of huN901-DM1 (BB-10901) in patients with relapsed and relapsed/ refractory CD56-positive multiple myeloma [abstract]. Blood. 2007; 110:1174.
167. Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006; 281:10540-10547.
168. Smith LM, Nesterova A, Alley SC, et al. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol Cancer Ther. 2006;5:1474- 1482.
169. Dijoseph JF, Dougher MM, Armellino DC, et al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21:2240-2245.
170. Junutula JR, Raab H, Bhakta S, et al. Site-specific conjugation of cytotoxic drugs to antibodies substantially improves the therapeutic window [abstract 2132]. Proc Am Assoc Cancer Res. 2008; in press.
171. Xie H, Audette C, Hoffee M, et al. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther. 2004;308:1073-1082.